<DOC>
	<DOCNO>NCT02090673</DOCNO>
	<brief_summary>The objective regulatory Post-Marketing Surveillance Korea reconfirm clinical usefulness Exenatide collecting , review , identify verify safety effectiveness information Exenatide general practice .</brief_summary>
	<brief_title>Post-Marketing Surveillance Study : 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Male female least 18 year age Patients initiate Exenatide treatment type 2 diabetes baseline , follow treat physician ' advice Patients , opinion treat physician , comply recommendation state relevant product information Are simultaneously participate different study include treatment intervention and/or investigational drug Are pregnant intention become pregnant within duration study Contraindications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>